Welcome to our dedicated page for ARS Pharms SEC filings (Ticker: SPRY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ARS Pharmaceuticals, Inc. filings document the public-company record for a biopharmaceutical issuer commercializing neffy, an epinephrine nasal spray for severe allergic reactions and anaphylaxis. The company’s 8-K filings report financial results, Regulation FD presentation updates, material agreements, product and commercialization disclosures, and legal or regulatory events involving neffy and related patent protections.
ARS Pharmaceuticals’ proxy materials describe board elections, shareholder voting matters, executive compensation, equity awards and audit oversight. Other filings identify its Nasdaq-listed common stock, capital-structure matters, credit arrangements involving ARS Pharmaceuticals Operations, Inc., and risk-related disclosures tied to product development, commercialization, intellectual property and regulatory pathways.
ARS Pharmaceuticals President Donn Casale received a large stock option grant tied to future service. The award covers 898,456 options to buy Common Stock at an exercise price of $7.96 per share, expiring on June 30, 2036. Following this grant, Casale holds 898,456 options directly. Vesting is long-term: 25% of the shares vest on June 1, 2027, with the remaining options vesting monthly over the next three years, encouraging retention and alignment with shareholders.
ARS Pharmaceuticals reported that an entity associated with RA Capital received a grant of stock options linked to its common stock. The award covers 30,000 options with an exercise price of $10.54 per share and expires on June 23, 2036.
These options vest in full on the earlier of June 24, 2027 or the company’s 2027 annual meeting of stockholders. According to the disclosure, Dr. Peter Kolchinsky holds the option for the benefit of RA Capital Healthcare Fund LP and RA Capital Nexus Fund II, L.P., and any net proceeds reduce advisory fees owed to RA Capital Management, L.P. The reporting persons disclaim beneficial ownership except for any pecuniary interest.
ARS Pharmaceuticals director Rajeev Dadoo received a new stock option grant. He was awarded options covering 30,000 shares of common stock at an exercise price of $10.54 per share, expiring on June 23, 2036. These options vest in full on the earlier of June 24, 2027 or the company’s 2027 annual stockholder meeting.
ARS Pharmaceuticals director Pratik Shah received a stock option grant covering 30,000 shares of common stock. The option has an exercise price of $10.54 per share and expires on June 23, 2036. According to the terms, all 30,000 options will vest on the earlier of June 24, 2027 or the company’s 2027 annual stockholder meeting.
This is a compensation-related award reported as an acquisition, with no open‑market buying or selling of ARS Pharmaceuticals shares disclosed in this filing.
ARS Pharmaceuticals director Kelly Michael received a stock option grant for 30,000 shares of common stock at an exercise price of $10.54 per share. The option expires on June 23, 2036 and will vest in full on the earlier of June 24, 2027 or the company’s 2027 annual stockholder meeting.
ARS Pharmaceuticals director Saqib Islam received a stock option grant covering 30,000 shares of Common Stock. The option has an exercise price of $10.54 per share and expires on June 23, 2036. These options vest in full on the earlier of June 24, 2027 or the company’s 2027 annual meeting of stockholders. Following this grant, Islam holds 30,000 stock options directly.
ARS Pharmaceuticals director Peter A. Thompson reported a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $10.54 per share and expire on June 23, 2036. They vest in full on the earlier of June 24, 2027 or the company’s 2027 annual meeting of stockholders. Under an agreement, the economic benefit from any securities issued under these options must be transferred to OrbiMed-related entities.
ARS Pharmaceuticals director Brent L. Saunders received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $10.54 per share and expire on June 23, 2036. They vest in full on the earlier of June 24, 2027 or the company’s 2027 annual meeting of stockholders.
ARS Pharmaceuticals director Phillip M. Schneider received a grant of stock options as compensation. On June 24, 2026, he was awarded options covering 30,000 shares of common stock with an exercise price of $10.54 per share. These options vest in full on the earlier of June 24, 2027 or the company’s 2027 annual stockholder meeting and expire on June 23, 2036. After this grant, Schneider holds 30,000 stock options directly, and the transaction does not involve any open-market buying or selling of shares.
ARS Pharmaceuticals director Laura Shawver received a new stock option grant, not an open-market trade. The Form 4 shows an award of options to acquire 30,000 shares of common stock at an exercise price of $10.54 per share. Following this grant, she holds 30,000 stock options directly. These options vest in full on the earlier of June 24, 2027 or the company’s 2027 annual stockholder meeting, according to the footnote. The options expire on June 23, 2036, giving a long exercise window tied to her board service.